February 7, 2023

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

Re:			Mineralys Therapeutics, Inc.
			Registration Statement on Form S-1, as amended
			File No. 333-269282

Ladies and Gentlemen:

In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Mineralys Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Thursday, February 9, 2023, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 4,210 copies of the Preliminary Prospectus dated February 2, 2023 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.

In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.

Very truly yours,

BOFA SECURITIES, INC.

EVERCORE GROUP L.L.C.

STIFEL, NICOLAUS & COMPANY, INCORPORATED

As Representatives of the several underwriters

[Signature Pages Follow]

---

BOFA SECURITIES, INC.
By:			/s/ Gerardo Ubaghs
			Name: Gerardo Ubaghs
			Title: Managing Director
EVERCORE GROUP L.L.C.
By:			/s/ Gloria Tang
			Name: Gloria Tang
			Title: Managing Director
STIFEL, NICOLAUS & COMPANY, INCORPORATED
By:			/s/ Kenneth Clausman
			Name: Kenneth Clausman
			Title: Managing Director

As representatives of the several underwriters

cc: Ilir Mujalovic, Shearman & Sterling LLP

[Signature Page to Acceleration Request Letter]